124 related articles for article (PubMed ID: 30804486)
1. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party.
Hübel K; Re A; Boumendil A; Finel H; Hentrich M; Robinson S; Wyen C; Michieli M; Kanfer E; Diez-Martin JL; Balsalobre P; Vincent L; Schroyens W; Santasusana JMR; Kröger N; Schiel X; Cwynarski K; Esquirol A; Sousa AB; Cattaneo C; Montoto S; Dreger P
Bone Marrow Transplant; 2019 Oct; 54(10):1625-1631. PubMed ID: 30804486
[TBL] [Abstract][Full Text] [Related]
2. Remission of HIV-related naïve and high-risk Burkitt's lymphoma treated by autologous stem cell transplantation plus cART.
Min H; Yang J; Wang S; Tao P; Song Y; Wang X; Li H; Yang X; Dong X; Wang FS; Shi M; Wang X; Xu R
Stem Cell Res Ther; 2018 Dec; 9(1):353. PubMed ID: 30572947
[TBL] [Abstract][Full Text] [Related]
3. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
Casulo C; Friedberg JW; Ahn KW; Flowers C; DiGilio A; Smith SM; Ahmed S; Inwards D; Aljurf M; Chen AI; Choe H; Cohen J; Copelan E; Farooq U; Fenske TS; Freytes C; Gaballa S; Ganguly S; Jethava Y; Kamble RT; Kenkre VP; Lazarus H; Lazaryan A; Olsson RF; Rezvani AR; Rizzieri D; Seo S; Shah GL; Shah N; Solh M; Sureda A; William B; Cumpston A; Zelenetz AD; Link BK; Hamadani M
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1163-1171. PubMed ID: 29242111
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
5. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
6. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
[TBL] [Abstract][Full Text] [Related]
7. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
8. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
9. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
[TBL] [Abstract][Full Text] [Related]
10. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
[TBL] [Abstract][Full Text] [Related]
11. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.
Besson C; Lancar R; Prevot S; Algarte-Genin M; Delobel P; Bonnet F; Meyohas MC; Partisani M; Oberic L; Gabarre J; Goujard C; Boue F; Coppo P; Costello R; Hendel-Chavez H; Mekerri N; Dos Santos G; Recher C; Delarue R; Casasnovas RO; Taoufik Y; Mounier N; Costagliola D;
AIDS; 2017 Nov; 31(18):2493-2501. PubMed ID: 28926410
[TBL] [Abstract][Full Text] [Related]
12. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
13. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
Besson C; Lancar R; Prevot S; Brice P; Meyohas MC; Marchou B; Gabarre J; Bonnet F; Goujard C; Lambotte O; Boué F; Mounier N; Partisani M; Raffi F; Costello R; Hendel-Chavez H; Algarte-Genin M; Trabelsi S; Marchand L; Raphael M; Taoufik Y; Costagliola D
Clin Infect Dis; 2015 Nov; 61(9):1469-75. PubMed ID: 26223997
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.
Bal S; Costa LJ; Sauter C; Litovich C; Hamadani M
Transplant Cell Ther; 2021 Jan; 27(1):55.e1-55.e7. PubMed ID: 32949754
[TBL] [Abstract][Full Text] [Related]
16. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
17. Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Othman T; Quan MA; Zhang S; Gaut D; Young PA; Mahmood O; Abdulhaq H; Shieh K; Reid J; Brem EA; Hariharan N; Heyman B; Tuscano J
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):749-756. PubMed ID: 37336714
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
[TBL] [Abstract][Full Text] [Related]
20. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
